ProCE Banner Activity

Strategies for Optimal HIV Treatment and Prevention: Answering the Questions on Switching ART With Virologic Suppression

Multimedia

Hear from expert faculty as they answer questions and discuss key considerations when determining whether and how to switch antiretroviral therapy in virologically suppressed individuals with HIV.

Released: October 11, 2022

Expiration: October 10, 2023

No longer available for credit.

Share

Faculty

Tristan J. Barber

Tristan J. Barber, MA, MD, FRCP

Honorary Associate Professor
Institute for Global Health
University College London
Consultant in HIV Medicine
Ian Charleson Day Centre
Royal Free Hospital
London, United Kingdom

Darcy Wooten

Darcy Wooten, MD, MS

Professor of Medicine
Division of Infectious Diseases and Global Public Health
University of California, San Diego
San Diego, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

ViiV Healthcare

Target Audience

This program is intended for physicians, registered nurses, pharmacists, nurse practitioners and physician associates/physician assistants, and other healthcare providers who care for persons with or at risk of HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess regimen options and patient-related factors when determining whether and how to modify therapy in virologically suppressed individuals

Faculty Disclosure

Primary Author

Tristan J. Barber, MA, MD, FRCP

Honorary Associate Professor
Institute for Global Health
University College London
Consultant in HIV Medicine
Ian Charleson Day Centre
Royal Free Hospital
London, United Kingdom

Tristan J. Barber, MA, MD, FRCP: consultant/advisor/speaker: Gilead Sciences, Merck, Roche, Theratechnologies, ViiV Healthcare; researcher: Roche, ViiV Healthcare; unrestricted educational grant holder: Gilead Sciences.

Darcy Wooten, MD, MS

Professor of Medicine
Division of Infectious Diseases and Global Public Health
University of California, San Diego
San Diego, California

Darcy Wooten, MD, has no relevant financial relationships to disclose.

Staff Disclosure

Staff

Jessica L. Adams, PharmD, AAHIVE

Scientific Director, Infectious Diseases
Clinical Care Options
New York, United States

Jessica Adams, PharmD, BCPS, has no relevant financial relationships to disclose.

Heli Desai, MSc

Heli Desai, MSc, has no relevant financial relationships to disclose.

Ian Murphy, PhD

Ian Murphy, PhD, has no relevant financial relationships to disclose.

Jenny Schulz, PhD

Associate Managing Editor, Hepatitis
Clinical Care Options, LLC

Jenny Schulz, PhD, has no relevant financial relationships to disclose.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant financial relationships to disclose.

Julie Skowronski, FNP-BC

Julie Skowronski, FNP-BC, has no relevant financial relationships to disclose.

Additional Information

Program Medium

This program has been made available online.

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

 

Goal


The goal of this activity is to deliver the interprofessional HIV management team sustained education that will improve their knowledge and competence in making care decisions that address the needs of their individual patients.